Month: May 2020

AS „Latvijas Gāze” aicina piedalīties uzņēmuma rīkotajā virtuālajā konferencē (vebinārā) 28. maijā plkst. 16:00 (pēc Latvijas laika). Lai piedalītos vebinārā, tam ir iepriekš jāreģistrējas – detalizēta informācija sniegta zemāk.Virtuālo konferenci (vebināru) vadīs un uz dalībnieku jautājumiem atbildēs AS „Latvijas Gāze” valdes priekšsēdētāja vietnieks Sebastians Grēblinghofs. Vebināra prezentācija notiks angļu valodā, taču būs iespēja uzdot jautājumus arī latviešu valodā.Vebināra ietvaros Sebastians Grēblinghofs analizēs AS “Latvijas Gāze” koncerna 2020. gada 3 mēnešu neauditētos finanšu rezultātus, kas tiks publicēti š.g. 27. maijā, kā arī informēs par aktualitātēm koncernā. Pēc prezentācijas uzņēmuma pārstāvis atbildēs uz vebināra dalībnieku jautājumiem.Ņemot vērā, ka vebināram atvēlētais laiks ir ierobežots, lūdzam Jūsu jautājumus...

NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the approval by the Australian Human Research Ethics Committee to initiate the First-in-Human (FIH) clinical study of ANAVEX®3-71 (AF710B), an orally-administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.This represents Anavex’s 2nd novel clinical sigma-1 and muscarinic receptor program parallel to ANAVEX®2-73 (blarcamesine). Anavex is developing ANAVEX®3-71...

CAMBRIDGE, Mass., May 21, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform. AAN’s annual meeting was cancelled due to COVID-19 and the virtual platform allows for all accepted oral and poster presentations to be presented. The materials linked below will be available for approximately 10 months. “We are pleased by the breadth of losmapimod data selected for presentation, which highlights the progress we’ve made to develop a treatment for patients with facioscapulohumeral muscular dystrophy (FSHD) and our approach to treating the root cause of genetically defined rare...

LONDON, Ontario, May 21, 2020 (GLOBE NEWSWIRE) — Indiva Limited (the “Company” or “Indiva”) (TSXV:NDVA) (OTCQX:NDVAF) is pleased to announce that it has secured distribution rights to ship its premium cannabis products to New Brunswick and Manitoba. These two new agreements extend Indiva’s distribution network to eight provinces. Indiva’s first shipments to Manitoba include INDIVA™ pre-rolls and THC capsules, and Bhang® Chocolate. Indiva expects that INDIVA™ and Bhang® products will be available in Manitoba stores within the next two weeks. New Brunswick recently received Bhang® Chocolate, which is now available for purchase at www.cannabis-nb.com.“We are proud to continue to grow our distribution network across Canada,” Niel Marotta, Indiva’s President and Chief Executive Officer, said. “As of today, we are nearly a nationwide...

TULSA, Okla., May 21, 2020 (GLOBE NEWSWIRE) — Educational Development Corporation (“EDC”, or the “Company”) (NASDAQ: EDUC) (http://www.edcpub.com) today reports net revenues and earnings per share results for the fiscal year ended February 29, 2020.Randall White, CEO of Educational Development Corporation, announced that for the fiscal year 2020, the Company reports net revenues of $113,011,900, a decrease of $5,799,400, or 4.9%, when compared to $118,811,300 for the previous year.  Fiscal 2020 net earnings totaled $5,645,100, compared to $6,678,400 in fiscal 2019, a decrease of 15.5%.  Fiscal year 2020 earnings per share were $0.68 compared to $0.81 the previous year, down 16.0% on a fully diluted basis.For the fiscal fourth quarter ended February 29, 2020, the Company reports net revenues of $20,161,900, a decrease of $3,463,500,...

Submission of New Drug Application

Q4 Revenue of $6.0 Billion Decreased 26% Reported and 25% OrganicQ4 GAAP Diluted EPS of $0.48; Q4 Non-GAAP Diluted EPS of $0.58Financial Results In-Line with Update Provided on April 21 and Consistent with Impact Felt Across MedTech IndustryFY20 Cash Flow from Operations of $7.2 Billion; FY20 Free Cash Flow of $6.0 Billion; Conversion of 97%Quarterly Dividend Increased to $0.58, Annual $2.32 from Prior $2.16; 43rd Consecutive Year of Dividend IncreasesDUBLIN, May 21, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2020, which ended April 24, 2020. The results were in-line with the update the company provided on April 21, 2020, which detailed the impact of the COVID-19 pandemic on its operations and financials. Medtronic’s results were also consistent with...

PUEBLO, CO, May 21, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE ‒ SGD Holdings, Ltd. (OTC PINK: SGDH), a Lessor, Consultant, and Property Manager in the Cannabis Industry in the State of Colorado, announces a Certificate of Occupancy for the Dispensary Property located at 601 Hwy 85/87 in Walsenburg, Colorado.Delmar Janovec, CEO, states, “On Friday, May 15, 2020, the City Building Inspector conducted the final inspection of the build-to-suit lease property located at 601 Hwy 85/87 in Walsenburg, Colorado. The building was approved for occupancy and our sub-lease tenant, C1B True Organics, LLC, can now begin to stock the retail store with Cannabis products, accessories, and C1B merchandise. We could not be more pleased with the end results of this extensive renovation project and once again the property developer has far exceeded our...

‒ Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 ‒‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through Six Months for Bone Mineral Density Data and Evaluate Additional Higher Doses of EB613 ‒‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒BOSTON and JERUSALEM, May 21, 2020 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced interim limited biomarker data from the ongoing Phase 2 clinical trial of EB613 in osteoporosis patients and results for the quarter ended March 31, 2020.  The study demonstrated statistically significant effects on the P1NP biomarker after one month of treatment (p